JP2024528039A5 - - Google Patents
Info
- Publication number
- JP2024528039A5 JP2024528039A5 JP2024505230A JP2024505230A JP2024528039A5 JP 2024528039 A5 JP2024528039 A5 JP 2024528039A5 JP 2024505230 A JP2024505230 A JP 2024505230A JP 2024505230 A JP2024505230 A JP 2024505230A JP 2024528039 A5 JP2024528039 A5 JP 2024528039A5
- Authority
- JP
- Japan
- Prior art keywords
- raf
- inhibitor
- administered
- mek
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163203555P | 2021-07-27 | 2021-07-27 | |
| US63/203,555 | 2021-07-27 | ||
| PCT/US2022/038434 WO2023009572A1 (en) | 2021-07-27 | 2022-07-27 | Combination therapy for treating abnormal cell growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024528039A JP2024528039A (ja) | 2024-07-26 |
| JP2024528039A5 true JP2024528039A5 (enExample) | 2025-08-04 |
Family
ID=85087234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024505230A Pending JP2024528039A (ja) | 2021-07-27 | 2022-07-27 | 異常な細胞成長を処置するための組み合わせ治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250049792A1 (enExample) |
| EP (1) | EP4376828A4 (enExample) |
| JP (1) | JP2024528039A (enExample) |
| KR (1) | KR20240041978A (enExample) |
| CN (1) | CN118103040A (enExample) |
| AU (1) | AU2022318885A1 (enExample) |
| CA (1) | CA3227498A1 (enExample) |
| IL (1) | IL310477A (enExample) |
| MX (1) | MX2024001248A (enExample) |
| WO (1) | WO2023009572A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115151533B (zh) | 2020-01-10 | 2025-08-08 | 医疗免疫工程公司 | Mek抑制剂及其治疗用途 |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| EP4595963A4 (en) * | 2022-09-30 | 2026-01-21 | Inxmed Nanjing Co Ltd | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND SUBSTANCE TO INDUCE IMMUNOGENEOUS CELL DEATH AND USE |
| WO2024173761A1 (en) * | 2023-02-17 | 2024-08-22 | Ikena Oncology, Inc. | Combinations comprising mek inhibitors for use in the treatment of cancer |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| CN121487951A (zh) | 2023-04-07 | 2026-02-06 | 锐新医药公司 | 大环ras抑制剂 |
| AU2024251341A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| EP4695261A1 (en) | 2023-04-14 | 2026-02-18 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| KR20260019479A (ko) * | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN122459678A (zh) | 2023-12-29 | 2026-07-24 | 百时美施贵宝公司 | KRAS抑制剂与Treg耗竭剂的组合疗法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016115376A1 (en) * | 2015-01-14 | 2016-07-21 | The Regents Of The University Of California | Detection and treatment of double drug resistant melanomas |
| WO2021047783A1 (en) * | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
| CN115151533B (zh) * | 2020-01-10 | 2025-08-08 | 医疗免疫工程公司 | Mek抑制剂及其治疗用途 |
-
2022
- 2022-07-27 CN CN202280063475.8A patent/CN118103040A/zh active Pending
- 2022-07-27 IL IL310477A patent/IL310477A/en unknown
- 2022-07-27 AU AU2022318885A patent/AU2022318885A1/en not_active Abandoned
- 2022-07-27 WO PCT/US2022/038434 patent/WO2023009572A1/en not_active Ceased
- 2022-07-27 CA CA3227498A patent/CA3227498A1/en active Pending
- 2022-07-27 EP EP22850215.9A patent/EP4376828A4/en active Pending
- 2022-07-27 MX MX2024001248A patent/MX2024001248A/es unknown
- 2022-07-27 KR KR1020247006593A patent/KR20240041978A/ko active Pending
- 2022-07-27 JP JP2024505230A patent/JP2024528039A/ja active Pending
- 2022-07-27 US US18/292,086 patent/US20250049792A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024540015A5 (enExample) | ||
| Aoyama et al. | Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer | |
| Liang et al. | Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC) | |
| Teng et al. | CIP2A is a predictor of poor prognosis in colon cancer | |
| JP2020514311A5 (enExample) | ||
| JP2023523323A5 (enExample) | ||
| JP2024519845A5 (enExample) | ||
| CN105120663B (zh) | 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物 | |
| JP2021524835A5 (enExample) | ||
| WO2017177962A1 (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| JP2017526662A5 (enExample) | ||
| JP2013511487A (ja) | Ｃｄｃ７阻害剤と抗新生物薬とを含む治療用の組み合わせ | |
| Jiang et al. | Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study. | |
| Zhang et al. | FNC, a novel nucleoside analogue, blocks invasion of aggressive non-Hodgkin lymphoma cell lines via inhibition of the Wnt/β-catenin signaling pathway | |
| JP2024528705A5 (enExample) | ||
| WO2017118401A1 (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
| Ilson | Immunotherapy in esophagogastric cancer | |
| JP2022501332A5 (enExample) | ||
| BR112020003585A2 (pt) | composição para uso no tratamento, prevenção ou retardamento da progressão de tumores sólidos que incluem câncer em um ser humano | |
| JP2024518712A5 (enExample) | ||
| Chi et al. | Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer | |
| JP2023550740A5 (enExample) | ||
| WO2019016928A1 (ja) | がん細胞の代謝の特異性に基づく新規抗悪性腫瘍剤 | |
| TW202120085A (zh) | 抗ccr4抗體抵抗性之癌症的治療劑 | |
| Bancewicz et al. | Adjuvant chemotherapy and immunotherapy for colorectal cancer: preliminary communication |